Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × indibulin × Clear all
NCT01113970 2013-01-30

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Alaunos Therapeutics

Phase 1/2 Unknown
60 enrolled
Breast

Breast Neoplasms

NCT00726687 2012-07-19

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1/2 Unknown
7 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡